[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368266-105":59,"doc-detail-368266-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cellular-interactions-within-the-immune-microenvironment-underpins-resistance-to-cell-cycle-inhibition-in-breast-cancers","Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers","","Immune evasion in breast cancer is driven by tumor microenvironment (TME) remodeling through communication with non-malignant cells, yet resistance-promoting interactions during CDK4/6 inhibition remain unclear. Using serial biopsies and longitudinal single-cell RNA sequencing in stage II–III high-risk ER+ patients treated with letrozole with or without ribociclib, the study links treatment escape to cytokine- and growth-factor–driven myeloid suppression of CD8+ T-cell crosstalk, with impaired T-cell activation during therapy. Ribociclib also directly dampens T-cell proliferation and activation in co-culture; exogenous IL-15 restores T-cell proliferation and improves efficacy by enhancing cancer cell killing. Overall, response depends on immune-cell composition, activation phenotypes, and communication networks.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cellular-interactions-within-the-immune-microenvironment-underpins-resistance-to-cell-cycle-inhibition-in-breast-cancers/368266/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cellular-interactions-within-the-immune-microenvironment-underpins-resistance-to-cell-cycle-inhibition-in-breast-cancers/368266.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does ribociclib resistance emerge in high-risk ER+ breast cancers during endocrine therapy?","Question",{"text":113,"@type":114},"Tumors that overcome ribociclib growth suppression upregulate cytokines and growth factors that drive immunosuppressive myeloid differentiation, reducing myeloid–CD8+ T-cell crosstalk through IL-15/18 signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What happens to T-cell activation and recruitment during treatment in tumors that grow on therapy?",{"text":118,"@type":114},"Treatment-growing tumors show diminished T-cell activation and reduced recruitment compared with the initial therapeutic response.",{"name":120,"@type":111,"acceptedAnswer":121},"What role does IL-15 play in ribociclib efficacy?",{"text":122,"@type":114},"Exogenous IL-15 improves CDK4/6 inhibitor efficacy by augmenting T-cell proliferation and increasing cancer cell killing by T cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368266,1790252507,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article [https://doi.org/10.1038/s41467-025-56279-x](https://doi.org/10.1038/s41467-025-56279-x)  \nCellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers  \nReceived: 4 April 2024  \n\n| Accepted: 13 January 2025 |\n| --- |\n| |\n| Check for updates |\n\nJason I. Grifﬁths1,2,6 , Patrick A. Cosgrove 1,6, Eric F. Medina1, Aritro Nath 1, Jinfeng Chen1, Frederick R. Adler 2,3, Jeffrey T. Chang 4, Qamar J. Khan5 &  \nAndrea H. Bild 1   \nImmune evasion by cancer cells involves reshaping the tumor microenvironment (TME)via communication with non-malignant cells. However, resistancepromoting interactions during treatment remain lesser known. Here we examine the composition, communication, and phenotypes of tumorassociated cells in serial biopsies from stage II and III high-risk estrogen receptor positive (ER+ ) breast cancers of patients receiving endocrine therapy (letrozole) as single agent or in combination with ribociclib, a CDK4/6-targeting cell cycle inhibitor. Single-cell RNA sequencing analyses on longitudinally collected samples show that in tumors overcoming the growth suppressive effects of ribociclib, ﬁrst cancer cells upregulate cytokines and growth factors that stimulate immune-suppressive myeloid differentiation, resulting in reduced myeloid cell-CD8 + T-cell crosstalk via IL-15/18 signaling. Subsequently, tumors growing during treatment show diminished T-cell activation and recruitment. In vitro, ribociclib does not only inhibit cancer cell growth but also T cell proliferation and activation upon co-culturing. Exogenous IL-15 improves CDK4/6 inhibitor efﬁcacy by augmenting T-cell proliferation and cancer cell killing by T cells. In summary, response to ribociclibin stage II and III high-risk ER + breast cancer depends on the composition, activation phenotypes and communication network of immune cells.  \nIn healthy tissues, interactions among epithelial, stromal and immune cells tightly regulate cell phenotypes, proliferation and tissue composition1. These cellular communication networks are disrupted in tumors, with a strengthening of growth-promoting signals and weakening of growth-inhibitory controls2–4. The milieu of communications between cancer and non-cancer cell types can engineer the tumor microenvironment (TME) to trigger the onset of malignancy, and drive disease progression and establishment of a metastatic niche5.  \nThe phenotype, communication and composition of non-cancer cells within the tumor inﬂuence treatment resistance, in addition to the genetic heterogeneity and evolution of cancer cells. Diverse noncancer cell types can modulate growth and survival signals inthe TME, potentially contributing to resistance and progression. For example, tumor-associated macrophages can differentiate into an immunesuppressive M2-like phenotype instead of an immune activating M1-like state, switching signals in the TME from an anti-cancer to a pro-  \n1Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, USA. 2Department of Mathematics, University of Utah 155South 1400 East, Salt Lake City, UT, USA. 3School of Biological Sciences, University of Utah 257South 1400 East, Salt Lake City, UT, USA. 4Department of Integrative Biology and Pharmacology, School of Medicine, School of Biomedical Informatics, UT Health Sciences Center at Houston, Houston, TX, USA. 5Division of Medical Oncology, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA. 6These authors contributed equally: Jason I. Grifﬁths, Patrick A. Cosgrove. [e-mail:](e-mail: jasonigriff@gmail.com)[ jasonigriff@gmail.com](e-mail: jasonigriff@gmail.com); [abild@coh.org](abild@coh.org)  \ncancer state6. Fibroblasts can promote extracellular matrix deposition to support cancer cell growth, and endothelial cells can support angiogenesis to supply oxygen and nutrients to a growing tumor7,8. Corrupt c","cbCaidNyYYMY5HXe","https://ap.wps.com/l/cbCaidNyYYMY5HXe","pdf",5234106,23,"English","# Background\n## Immune communication in tumor microenvironment\n# Study design and methods\n## Serial biopsies and longitudinal single-cell RNA sequencing\n# Key findings\n## Escape mechanisms during ribociclib treatment\n## Effects on T-cell activation and recruitment\n## In vitro validation and IL-15 rescue\n# Implications for therapy","[{\"question\":\"How does ribociclib resistance emerge in high-risk ER+ breast cancers during endocrine therapy?\",\"answer\":\"Tumors that overcome ribociclib growth suppression upregulate cytokines and growth factors that drive immunosuppressive myeloid differentiation, reducing myeloid–CD8+ T-cell crosstalk through IL-15/18 signaling.\"},{\"question\":\"What happens to T-cell activation and recruitment during treatment in tumors that grow on therapy?\",\"answer\":\"Treatment-growing tumors show diminished T-cell activation and reduced recruitment compared with the initial therapeutic response.\"},{\"question\":\"What role does IL-15 play in ribociclib efficacy?\",\"answer\":\"Exogenous IL-15 improves CDK4/6 inhibitor efficacy by augmenting T-cell proliferation and increasing cancer cell killing by T cells.\"}]","Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers | PDF",1790175944,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25380eb5cd59e7067f6b714bcd175286.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3eded6792833403b418ad076b461783.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/070307d453d6035a7299c79eff60e736.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a44d0f6a7a4970b34412ab4b3159b6d.webp",980,1301]